Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results

Oric Pharmaceuticals ( (ORIC) ) has issued an update.

On December 6, 2025, Oric Pharmaceuticals presented an update on its enozertinib (ORIC-114) program, highlighting data from a Phase 1b trial. The update revealed that enozertinib shows promising systemic and intracranial activity in EGFR-mutated NSCLC, potentially establishing a best-in-class profile. With no significant off-target toxicity and a manageable safety profile, enozertinib could address a significant commercial opportunity in the U.S., estimated at $3.0 to $3.5 billion annually, targeting approximately 9,000 patients with NSCLC.

The most recent analyst rating on (ORIC) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Spark’s Take on ORIC Stock

According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.

Oric Pharmaceuticals’ overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company’s stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.

To see Spark’s full report on ORIC stock, click here.

More about Oric Pharmaceuticals

Oric Pharmaceuticals operates in the pharmaceutical industry, focusing on the development of innovative therapies for cancer treatment. The company is engaged in creating products that target specific genetic mutations in cancer cells, with a primary market focus on non-small cell lung cancer (NSCLC).

Average Trading Volume: 1,366,066

Technical Sentiment Signal: Buy

Current Market Cap: $1.07B

For an in-depth examination of ORIC stock, go to TipRanks’ Overview page.